ZURICH, Switzerland, July 8,
2019 /PRNewswire/ -- Bruker today announced that it has
acquired PMOD Technologies LLC, a highly respected provider of
research-use-only software for preclinical and molecular imaging,
with a focus on molecular quantification and pharmacokinetic
modeling. The PMOD software is widely used for the analysis of
positron emission tomography (PET) studies in neurology, cardiology
and oncology, both for preclinical and human molecular imaging
research. Founded in 2003 as a University Hospital Zurich
spin-off, PMOD Technologies is based in Zurich and
has an innovative development team in Warsaw, Poland. The acquisition confirms
Bruker's commitment to provide intuitive end-to-end solutions that
make image analysis and quantitative knowledge extraction in
nuclear molecular imaging research more productive and precise.
Financial terms of the acquisition were not disclosed, and PMOD
continues to be managed by its senior management team. The PMOD
software continues to remain vendor-neutral and
platform-independent, and PMOD's outstanding customer support will
be maintained.
PMOD extends Bruker's portfolio of imaging software for clinical
research and further enhances Bruker's expertise in nuclear
molecular imaging. The portfolio now encompasses two leading-edge
imaging research software packages used in magnetic resonance
imaging (MRI) and nuclear molecular imaging (NMI) translational
research: ParaVision® 360 and
PMOD.
Dr. Wulf I. Jung, President of
Bruker's Preclinical Imaging Division, stated: "With the PMOD
acquisition, Bruker is broadening its support for translational
research with outstanding imaging tools, from highest-performance
preclinical MRI, PET/SPECT and microCT systems to state-of-the-art
software. Preclinical PET/MR is a fast-growing market, and the
expertise of the PMOD team will further strengthen our quantitative
molecular imaging solutions."
Dr. Cyrill Burger, CEO of PMOD,
commented: "Our team is delighted to join Bruker, a leading
provider of preclinical imaging solutions renowned for their
innovation and dedication to excellence. Our combined expertise
will accelerate the development and integration of novel molecular
imaging applications, answering the growing demand for innovative
research tools by translational scientists."
About PMOD
PMOD Technologies aims to equip researchers with best-in-class
software tools for biomedical imaging research in humans and
animals. The PMOD suite of software tools is a comprehensive
platform for quantitative imaging and is a leading solution for PET
kinetic modelling and parametric mapping. PMOD software includes
solutions for image registration, automated volume-of-interest
definition in neurology, oncology and cardiology, radiomics feature
extraction, 3D image visualization and computational fluid dynamics
(CFD) modelling. PMOD has an expanding customer base of more than
600 sites, with an estimated 2,000 active users worldwide.
Interactive and responsive collaborations with leading imaging
research institutions ensure that methodology and scope of the PMOD
software remain at the leading edge. For more information please
visit: www.pmod.com
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker's high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research, and clinical microbiology. For more
information, please visit: www.bruker.com.
Investor Contact:
Pamela
Clark
Investor Relations
Bruker Corporation
T: +1 (978) 663-3660, ext. 1479
E: Investor.Relations@bruker.com
Media
Contact:
Dr. Thorsten
Thiel
VP of Group Marketing
Bruker BioSpin
Group
T: +49 (721)
5161–6500
E: thorsten.thiel@bruker.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bruker-announces-acquisition-of-preclinical-and-molecular-imaging-research-software-provider-pmod-technologies-llc-300880514.html
SOURCE Bruker Corporation